OptiNose (OPTN) - Net Assets
Based on the latest financial reports, OptiNose (OPTN) has net assets worth $-61.37 Million USD as of March 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($114.85 Million) and total liabilities ($176.22 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check asset resilience ratio of OptiNose to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-61.37 Million |
| % of Total Assets | -53.43% |
| Annual Growth Rate | N/A |
| 5-Year Change | -694.58% |
| 10-Year Change | N/A |
| Growth Volatility | 160.77 |
OptiNose - Net Assets Trend (2015–2024)
This chart illustrates how OptiNose's net assets have evolved over time, based on quarterly financial data. Also explore OPTN total assets for the complete picture of this company's asset base.
Annual Net Assets for OptiNose (2015–2024)
The table below shows the annual net assets of OptiNose from 2015 to 2024. For live valuation and market cap data, see OPTN stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $-40.36 Million | +53.40% |
| 2023-12-31 | $-86.61 Million | -52.95% |
| 2022-12-31 | $-56.62 Million | -160.08% |
| 2021-12-31 | $-21.77 Million | -420.74% |
| 2020-12-31 | $6.79 Million | -88.98% |
| 2019-12-31 | $61.58 Million | -48.08% |
| 2018-12-31 | $118.61 Million | -23.23% |
| 2017-12-31 | $154.50 Million | +4125.43% |
| 2016-12-31 | $-3.84 Million | +85.86% |
| 2015-12-31 | $-27.15 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to OptiNose's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 58066200000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $10.00K | % |
| Other Comprehensive Income | $-84.00K | % |
| Other Components | $701.63 Million | % |
| Total Equity | $-40.36 Million | 100.00% |
OptiNose Competitors by Market Cap
The table below lists competitors of OptiNose ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Taiwan Takisawa Technology Co Ltd
TWO:6609
|
$97.25 Million |
|
New Delhi Television Limited
NSE:NDTV
|
$97.25 Million |
|
GIIR Inc
KO:035000
|
$97.32 Million |
|
Company K Partners Limited
KQ:307930
|
$97.32 Million |
|
Global Lights Acquisition Corp Ordinary Shares
NASDAQ:GLACF
|
$97.20 Million |
|
GEA Grenobl. Elect.
PA:GEA
|
$97.20 Million |
|
Stella Holdings Bhd
KLSE:5006
|
$97.18 Million |
|
Chariot Oil & Gas Limited
F:C62
|
$97.17 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in OptiNose's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -86,606,000 to -40,360,000, a change of 46,246,000.
- Net loss of 21,541,000 reduced equity.
- Share repurchases of 282,000 reduced equity.
- New share issuances of 55,477,000 increased equity.
- Other factors increased equity by 12,592,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-21.54 Million | -53.37% |
| Share Repurchases | $282.00K | -0.7% |
| Share Issuances | $55.48 Million | +137.46% |
| Other Changes | $12.59 Million | +31.2% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares OptiNose's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2015-12-31 | $-1.02 | $9.60 | x |
| 2016-12-31 | $-0.14 | $9.60 | x |
| 2017-12-31 | $14.05 | $9.60 | x |
| 2018-12-31 | $2.98 | $9.60 | x |
| 2019-12-31 | $1.47 | $9.60 | x |
| 2020-12-31 | $0.14 | $9.60 | x |
| 2021-12-31 | $-0.38 | $9.60 | x |
| 2022-12-31 | $-0.66 | $9.60 | x |
| 2023-12-31 | $-0.77 | $9.60 | x |
| 2024-12-31 | $-3.97 | $9.60 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently OptiNose utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -27.54%
- • Asset Turnover: 0.61x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-174.71%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | 0.00% | -33310.59% | 0.01x | 0.00x | $-25.60 Million |
| 2016 | 0.00% | 47.61% | 1.14x | 0.00x | $23.00 Million |
| 2017 | -31.65% | -30186.42% | 0.00x | 1.56x | $-64.35 Million |
| 2018 | -89.92% | -1509.67% | 0.03x | 1.83x | $-118.52 Million |
| 2019 | -176.91% | -314.59% | 0.20x | 2.80x | $-115.10 Million |
| 2020 | -1448.59% | -200.20% | 0.26x | 27.82x | $-99.01 Million |
| 2021 | 0.00% | -109.37% | 0.45x | 0.00x | $-79.47 Million |
| 2022 | 0.00% | -100.16% | 0.53x | 0.00x | $-70.73 Million |
| 2023 | 0.00% | -49.99% | 0.66x | 0.00x | $-26.82 Million |
| 2024 | 0.00% | -27.54% | 0.61x | 0.00x | $-17.50 Million |
Industry Comparison
This section compares OptiNose's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $225,911,116
- Average return on equity (ROE) among peers: -46.16%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| OptiNose (OPTN) | $-61.37 Million | 0.00% | N/A | $97.22 Million |
| Aurora Cannabis Inc (ACB) | $5.74 Million | -99.73% | 2.19x | $193.38 Million |
| Akanda Corp (AKAN) | $-5.03 Million | 0.00% | 0.00x | $1.51 Million |
| Akebia Ther (AKBA) | $74.01 Million | -330.87% | 6.15x | $310.74 Million |
| Alkermes Plc (ALKS) | $1.21 Billion | -17.23% | 0.43x | $4.62 Billion |
| Amylyx Pharmaceuticals Inc (AMLX) | $433.43 Million | 11.37% | 0.19x | $1.63 Billion |
| Amphastar P (AMPH) | $337.33 Million | 1.34% | 0.35x | $862.03 Million |
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | $366.97 Million | 2.90% | 9.74x | $3.81 Billion |
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | $-375.58 Million | 0.00% | 0.00x | $3.57 Billion |
| Anika Therapeutics Inc (ANIK) | $17.06 Million | -17.82% | 0.18x | $197.93 Million |
| ANI Pharmaceuticals Inc (ANIP) | $195.70 Million | -11.52% | 1.36x | $1.80 Billion |
About OptiNose
OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists. It offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well … Read more